A Japanese Phase 1 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs ME 401 (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 12 Jun 2019 Status changed from planning to recruiting.
- 15 Nov 2018 New trial record
- 05 Nov 2018 According to a MEI Pharma media release, Kyowa Hakko Kirin plans to initiate this Phase 1 study in Japan in 2019.